204 results
424B3
CYCC
Cyclacel Pharmaceuticals Inc
14 Feb 24
Prospectus supplement
4:06pm
through five dose levels. The study is currently not recruiting awaiting the determination of the RP2D from 065-101.
Chronic lymphocytic leukemia … .
In April 2022, a publication in the journal, Leukemia, from The University of Texas MD Anderson Cancer Center reported preclinical data against chronic
8-K
EX-10.2
CYCC
Cyclacel Pharmaceuticals Inc
4 May 23
Departure of Directors or Certain Officers
4:06pm
) addiction to drugs or chronic alcoholism or (E) any conviction of, or plea of nolo contendere to, a crime (other than a traffic violation) under the laws
8-K
EX-10.1
z5r zriad
4 May 23
Departure of Directors or Certain Officers
4:06pm
8-K
EX-99.1
00twu246254rsjml4p9
10 Aug 22
Cyclacel Pharmaceuticals Reports SECOND quarter 2022 financial results
4:15pm
8-K
EX-99.1
fvu9a xvt3v
11 May 22
Cyclacel Pharmaceuticals Reports first quarter 2022 financial results and provides business update
4:11pm
424B5
lpfou4gqbqgkxcs
30 Mar 22
Prospectus supplement for primary offering
5:28pm
424B5
d22ncs ubgivmk4i
12 Aug 21
Prospectus supplement for primary offering
5:07pm
8-K/A
EX-10.1
fkqmteu3nv
12 Jul 21
Departure of Directors or Certain Officers
4:06pm
8-K/A
EX-10.2
168hss82heo20 2b9j
12 Jul 21
Departure of Directors or Certain Officers
4:06pm
8-K
EX-10.1
tmtn wj2w60y2
17 Jun 21
Departure of Directors or Certain Officers
4:11pm
8-K
EX-10.2
ud3myw6k
17 Jun 21
Departure of Directors or Certain Officers
4:11pm
424B5
tuda87 1ttt
12 Mar 21
Prospectus supplement for primary offering
9:41pm
424B5
8sxwwf
11 Mar 21
Prospectus supplement for primary offering
4:06pm
424B5
ad21ndeymnydmdrgb0
22 Dec 20
Prospectus supplement for primary offering
8:06am